Before participating in CATALYST, patients must complete the screening process at one of the study centers. Eligible patients will receive either BARD capsules or placebo capsules and will be instructed to take the capsules once daily for 24 weeks. The study team will follow patients closely and will conduct visits through the duration of participation. The investigational drug, study-related procedures, and doctor visits will be provided at no cost to you. You may receive compensation for your time and travel.
The chart below shows the different stages of study participation.
Study Participation is complete at approximately week 28.
Reata plans to provide bardoxolone methyl (active drug), through an extension study or program, to all patients who complete CATALYST. At the discretion of your doctor, you may participate in the extension study or program, until the drug is commercially available or the study/program is stopped.